Quarterly ResultMay 15, 2026, 08:02 AM
Lifeward Q1 Revenue $3.9M, Net Loss $10.8M; Strategic Transaction Closed
AI Summary
Lifeward Ltd. announced its financial results for the first quarter ended March 31, 2026, reporting a revenue of $3.9 million and a net loss of $10.8 million. The company successfully closed a strategic transaction with Oramed, receiving $10 million in financing, and acquired Oratech, which brings $6.5 million in cash and Protein Oral Delivery™ biomed technology. Lifeward also acquired upper body exoskeleton technology and reduced its quarterly operating cash burn by 33% year-over-year. The company will delay filing its Form 10-Q to finalize accounting for the strategic transaction.
Key Highlights
- Strategic transaction with Oramed closed, bringing $10 million in financing.
- Acquired Oratech, adding $6.5 million in cash and Protein Oral Delivery™ platform.
- Q1 2026 revenue was $3.9 million, a 22% decrease from $5.0 million in Q1 2025.
- Q1 2026 GAAP net loss was $10.8 million, or $6.70 per share, compared to $4.8 million in Q1 2025.
- Operating cash burn reduced by 33% year-over-year to $3.7 million in Q1 2026.
- ReWalk personal exoskeleton sales increased by 11% to $1.6 million.
- AlterG product and services revenue declined 38% to $2.1 million due to timing issues.
- Cash and cash equivalents increased to $11.4 million as of March 31, 2026, from $2.2 million at Dec 31, 2025.
Price Impact
More from LFWD